The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1-/- murine model of ovarian cancer

Biochemical and Biophysical Research Communications

Volumn 463, Issue 4, 2015, Pages 551-556

  Huang, Jing ^a,b   Wang, Lei ^a   Cong, Zhongyi ^a,c   Amoozgar, Zohreh ^a,d   Kiner, Evgeny ^a   Xing, Deyin ^e   Orsulic, Sandra ^f   Matulonis, Ursula ^a   Goldberg, Michael S ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c JILIN UNIVERSITY   (China)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

BMN 673; Immune microenvironment; Ovarian cancer; PARP1

Indexed keywords

BRCA1 PROTEIN; GAMMA INTERFERON; TALAZOPARIB; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, MOUSE; PHTHALAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL STRESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENCY; FEMALE; HOMOLOGOUS RECOMBINATION; IMMUNOREGULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; OVARY TUMOR; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE;

MURINAE; MUS;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENES, BRCA1; MICE; MICE, KNOCKOUT; OVARIAN NEOPLASMS; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84936891045     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.05.083     Document Type: Article

References (24)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M.J. Thun Cancer statistics CA. Cancer J. Clin. 57 2007 43 66
2. B.T. Hennessy, R.L. Coleman, and M. Markman Ovarian cancer Lancet 374 2009 1371 1382
3. K. Do, and A.P. Chen Molecular pathways: targeting PARP in cancer treatment Clin. Cancer Res. 19 2013 977 984
4. C.J. Lord, and A. Ashworth The DNA damage response and cancer therapy Nature 481 2012 287 294
5. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat. Rev. Cancer 10 2010 293 301
6. M. Leung, D. Rosen, S. Fields, A. Cesano, and D.R. Budman Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality Mol. Med. 17 2011 854 862
7. Y. Shen, F.L. Rehman, Y. Feng, J. Boshuizen, I. Bajrami, and R. Elliott BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency Clin. Cancer Res. 19 2013 5003 5015
8. J. Murai, S.-Y.N. Huang, A. Renaud, Y. Zhang, J. Ji, and S. Takeda Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol. Cancer Ther. 13 2014 433 443
9. Z.A. Wainberg, J.S. de Bono, L. Mina, J. Sachdev, L.A. Byers, and R. Chugh Abstract C295: update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors Mol. Cancer Ther. 12 2014 C295-C295
10. H. Qiu Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer-letter Clin. Cancer Res. 20 2014 2236
11. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, and P. Mottram Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
12. M. Tomsová, B. Melichar, I. Sedláková, and I. Steiner Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma Gynecol. Oncol. 108 2008 415 420
13. D. Xing, and S. Orsulic A mouse model for the molecular characterization of brca1-associated ovarian carcinoma Cancer Res. 66 2006 8949 8953
14. L. Zhang, N. Yang, J.-R.C. Garcia, A. Mohamed, F. Benencia, and S.C. Rubin Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma Am. J. Pathol. 161 2002 2295 2309
15. C. Marchetti, L. Imperiale, M.L. Gasparri, I. Palaia, S. Pignata, and T. Boni Olaparib, PARP1 inhibitor in ovarian cancer Expert Opin. Investig. Drugs 21 2012 1575 1584
16. E.Z. Zsiros, P. Duttagupta, D. Dangaj, H. Li, R. Frank, and T. Garrabrant The ovarian cancer chemokine landscape is conducive to homing of vaccine-primed and CD3/CD28 costimulated T cells prepared for adoptive therapy Clin. Cancer Res. 2015 Epub ahead of print
17. T.C.G.A.R. Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
18. S. Ostrand-Rosenberg, and P. Sinha Myeloid-derived suppressor cells: linking inflammation and cancer J. Immunol. 182 2009 4499 4506
19. E. Sato, S.H. Olson, J. Ahn, B. Bundy, H. Nishikawa, and F. Qian Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 102 2005 18538 18543
20. M.A. Geller, S. Cooley, P.L. Judson, R. Ghebre, L.F. Carson, and P.A. Argenta A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer Cytotherapy 13 2011 98 107
21. E.R. Kost, D.G. Mutch, and T.J. Herzog Interferon-gamma and tumor necrosis factor-alpha induce synergistic cytolytic effects in ovarian cancer cell lines-roles of the TR60 and TR80 tumor necrosis factor receptors Gynecol. Oncol. 72 1999 392 401
22. S.E. Street, E. Cretney, and M.J. Smyth Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis Blood 97 2001 192 197
23. N. Leffers, M.J.M. Gooden, R.A. de Jong, B.-N. Hoogeboom, K.A. ten Hoor, and H. Hollema Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol. Immunother. 58 2009 449 459
24. N.A. Rizvi, M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, and J.J. Havel Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer Science 348 2015 124 128